Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

mass. movers

Aegerion climbs a second straight day

Aegerion’s Juxtapid drug is used to treat cholesterol disease.

istockphoto.com

Aegerion’s Juxtapid drug is used to treat cholesterol disease.

Continue reading below

Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com